Study summary

A blood test showed which second drug works for which mutation

INTRIGUE blood test analysis · 362 people, exploratory analysis of a phase 3 trial · Published January 2024, Nature Medicine

14.2 mobefore growth with ripretinib for KIT exon 11+17/18, vs 1.5 with sunitinib

What was tested

An analysis of tumor DNA in the blood of people in the INTRIGUE trial of ripretinib against sunitinib after imatinib.

What they found

With KIT exon 11 + 13/14 mutations, sunitinib worked better (15.0 vs 4.0 months).
With KIT exon 11 + 17/18 mutations, ripretinib worked better (14.2 vs 1.5 months).

What it means

Blood-based mutation testing may guide the second drug. A confirmatory trial (INSIGHT) is testing this.

Nat Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.